Anika Therapeutics (ANIK) Enterprise Value (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Enterprise Value data on file, last reported at -$66.8 million in Q1 2026.

• Enterprise Value for Q1 2026 came in at -$66.8 million, up 11.37% year-over-year; the trailing twelve-month figure through Mar 2026 was -$66.8 million (up 11.37% YoY), and the FY2025 annual result was -$81.2 million, down 2.46% from the prior year.
• Enterprise Value advanced to -$66.8 million in Q1 2026 per ANIK's latest filing, from -$81.2 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$66.8 million in Q1 2026 and troughed at -$123.6 million in Q2 2022.
• A 5-year average of -$96.9 million and a median of -$96.6 million in 2024 frame the typical range for Enterprise Value.
• The sharpest annual moves came in 2022 and 2025: Enterprise Value sank 34.04% in 2022, then rose 25.17% in 2025.
• A 5-year view of Enterprise Value shows it stood at -$121.0 million in 2022, then advanced by 21.38% to -$95.1 million in 2023, then climbed by 16.7% to -$79.2 million in 2024, then declined by 2.46% to -$81.2 million in 2025, then rose by 17.72% to -$66.8 million in 2026.
• Business Quant data shows ANIK's Enterprise Value at -$66.8 million in Q1 2026, -$81.2 million in Q4 2025, and -$80.2 million in Q3 2025.